[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psittacosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psittacosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100620072","phase-3-adaptive-rct-of-corticosteroids-for-severe-chlamydia-psittaci-pneumonia-in-adults-100620072",false,"NCT07352865","Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults","An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Chlamydia Psittaci Community-Acquired Pneumonia in Adults","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Admission to the Intensive Care Unit (ICU).\n* Meeting the diagnostic criteria for community-acquired pneumonia (CAP).\n* Meeting at least one of the major diagnostic criteria for severe pneumonia:\n\n  (i) Requirement for endotracheal intubation and mechanical ventilation;\n\n(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.\n\n-Or simultaneously fulfilling three of the minor criteria:\n\n(i) Respiratory rate ≥ 30 breaths\u002Fmin;\n\n(ii) PaO₂\u002FFiO₂ ≤ 250 mmHg;\n\n(iii) Multilobar infiltrates;\n\n(iv) Altered mental status and\u002For disorientation;\n\n(v) Blood urea nitrogen ≥ 20 mg\u002FdL (7.12 mmol\u002FL);\n\n(vi) Leukopenia (white blood cell count \\\u003C 4 × 10⁹\u002FL);\n\n(vii) Thrombocytopenia (platelet count \\\u003C 100 × 10⁹\u002FL);\n\n(viii) Hypothermia (core temperature \\\u003C 36 °C);\n\n(ix) Hypotension (systolic blood pressure \\\u003C 90 mmHg) requiring aggressive fluid resuscitation.\n\n* Confirmed Chlamydia psittaci etiology (psittacosis): at least one positive nucleic acid test (PCR\u002FRT-PCR) or next-generation sequencing (NGS) result for Chlamydia psittaci in respiratory specimens (respiratory secretions, throat swabs, or bronchoalveolar lavage fluid).\n* Severe community-acquired pneumonia (SCAP) patients admitted to the emergency department\u002Fward\u002FICU due to respiratory failure within \\\u003C 72 hours.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients receiving vasopressor therapy for septic shock at the time of enrollment.\n* Terminally ill patients (expected survival \\\u003C30 days, e.g., advanced malignancy).\n* Clinical history suggesting overt aspiration.\n* Documented active gastrointestinal bleeding.\n* Presence of cystic fibrosis, obstructive pneumonia, active influenza, pulmonary tuberculosis, or fungal infection.\n* Active viral hepatitis or active herpesvirus infection.\n* Bone marrow suppression or HIV infection.\n* Refusal of mechanical ventilation and endotracheal intubation.\n* Uncontrolled hyperglycemia (diabetic ketoacidosis with blood ketones \\>3 mmol\u002FL, or hyperosmolar hyperglycemic state with blood glucose \\>33.3 mmol\u002FL and elevated osmolality).\n* Known allergy to corticosteroids.\n* Patients requiring anti-inflammatory corticosteroids or replacement hydrocortisone for any reason, or those already receiving prednisone \\>15 mg\u002Fday (or equivalent dose of another corticosteroid).\n* Pregnant or breastfeeding women.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Severe community-acquired pneumonia caused by psittacosis is a form of atypical-pathogen community-acquired pneumonia that often requires critical care management. It can occur in immunocompetent adults, has an abrupt onset and rapid progression, and may quickly deteriorate to profound hypoxemia, acute respiratory distress syndrome, and multiple organ dysfunction, frequently necessitating ICU admission. In a multicenter cohort from 19 tertiary hospitals in China with metagenomic next-generation sequencing (mNGS)-confirmed severe CAP complicated by acute hypoxemic respiratory failure, approximately 44% of patients required invasive mechanical ventilation and ICU mortality was 8.9%, indicating a substantial risk of death and severe morbidity among critically ill patients. The World Health Organization (WHO) reported an increase in cases across several European countries from 2023 to early 2024, with five deaths, suggesting that the disease burden and public health significance of psittacosis may have been underestimated for a prolonged period.\n\nAt present, the cornerstone of psittacosis pneumonia management is early recognition and timely pathogen-directed antibiotic therapy (tetracyclines, particularly doxycycline, as first-line treatment), together with well-established organ-support strategies. Optimizing comprehensive management beyond early standard supportive care and guideline-concordant antimicrobial therapy (including targeted antibiotics and organ support) to further reduce mortality in severe psittacosis pneumonia is therefore of major clinical importance for improving outcomes in critically ill patients and alleviating the burden on families and society. Accordingly, we plan to conduct an adaptive, randomized, open-label, controlled trial to evaluate the efficacy and safety of adjunctive corticosteroid regimens at different doses, in addition to early standard supportive care, for reducing mortality in patients with severe psittacosis pneumonia.",[26],"Psittacosis",[26,28,29,30],"community-acquired pneumonia","adaptive randomised controled trial","corticosteroids","NOT_YET_RECRUITING","2026-01-13",{"date":34,"type":35},"2026-01-20","ACTUAL",{"date":37,"type":20},"2026-01-15",{"date":39,"type":20},"2028-11-30",{"name":41,"class":42},"Qingyuan Zhan","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":74,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100582154","serological-measurement-of-montpellier-professionals-contacts-with-infectious-agents-responsible-for-animal-borne-diseases-100582154","NCT06859619","Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases","Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.","SEZAM","Inclusion Criteria:\n\n* Age 18 or over\n* Consultant in an infectious diseases department\n* Have given written consent to participate in the study\n* Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.\n\nExclusion Criteria:\n\n* \\- Pregnant and breast-feeding women\n* Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)\n* Participants who are not fluent in French and who do not have a support person capable of reading French.\n* Persons unable to express their consent.\n* Persons participating in another research project with an exclusion period still in progress.\n* Persons not affiliated to a social security scheme or not benefiting from such a scheme.",{"count":52,"type":20},183,[54],"NA","Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.\n\nThe aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.\n\nDescribing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.",[57,58,59,60,61,62,26,63,64,65,66,67,68,69,70,71,72,73],"Leishmaniasis","Leptospirosis","Brucellosis","Q Fever","Rickettsiosis","Tularemia","Lyme Disease","Tick-borne Encephalitis","Hantaviral Infection Nos","Hepatitis E","Dengue Virus","Zika Virus","Chikungunya Virus Infection","West Nile Virus","Usutu Virus","Toscana Virus","Crimean-Congo Haemorrhagic Fever Virus",[75,58,59,76,77,78,79,80,81,82,83,84,85,86,62,26,87,88],"Leishmaniasis,","Zika virus","Q fever, Rickettsiosis","Lyme disease","Tick-borne encephaliti","Hantavirus","Hepatitis E virus","Dengue virus","Chikungunya virus","West-Nile virus","Usutu virus","Toscana virus","Crimean-Congo haemorrhagic fever virus","epidemiology","2025-02-27",{"date":91,"type":35},"2025-03-05",{"date":93,"type":20},"2025-03-03",{"date":95,"type":20},"2025-10-03",{"name":97,"class":42},"University Hospital, Montpellier",1]